权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

University of Pennsylvania HIV Clinical Trials Unit

宾夕法尼亚大学艾滋病毒临床试验单位

基本信息

批准号：
10304893
负责人：
Ian Frank
金额：
$ 331.3万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-02-01 至 2027-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10304893
关键词：
AIDS clinical trial group AIDS prevention Achievement Acquired Immunodeficiency Syndrome Adherence Adolescent Adult Affect Anti-Retroviral Agents Behavior Therapy Behavioral Research Biology Cardiovascular Diseases Caring Cells Chronic Kidney Failure Cities Clinical Clinical Investigator Clinical Research Clinical Trials Clinical Trials Unit Communities Conduct Clinical Trials Consequences of HIV Diagnosis Disease Outbreaks Drug Interactions Dyslipidemias Effectiveness Epidemic Evaluation Event Faculty Failure Goals HIV HIV Infections HIV prevention trial HIV therapy HIV vaccine Hepatitis B Virus Heterosexuals Human immunodeficiency virus test Immune response Immunologics Impairment Incentives Individual Infection Infection Control Infrastructure Injectable Injecting drug user International Investigation Leadership Maintenance Therapy Medical Mentors Monoclonal Antibodies Mucous Membrane Network Infrastructure New Agents Obesity Oral Outcome Pathogenesis Pennsylvania Persons Phenotype Philadelphia Physical Function Population Populations at Risk Positioning Attribute Prevention Prevention strategy Protocols documentation Recovery Research Research Personnel Resources Risk Risk Behaviors Role Science Site Structure Support Groups Testing Therapeutic Training Treatment-related toxicity Tuberculosis Universities Virus Activation Vision Work antiretroviral therapy career development cis-female clinical research site clinical trial implementation comorbidity cost efficient design frailty gender nonconforming immune activation immune function implantable device improved latent HIV reservoir medical schools men who have sex with men microbicide neutralizing monoclonal antibodies next generation non-alcoholic fatty liver disease novel novel therapeutics pre-exposure prophylaxis prevent preventive intervention protocol development purge response senescence shared decision making symposium therapy design transgender treatment as prevention uptake vaccine trial

项目摘要

ABSTRACT The University of Pennsylvania HIV Clinical Trials Unit (Penn HIV CTU) will build on its current infrastructure and further its commitment to provide scientific leadership to advance the science of HIV treatment and prevention within three HIV Clinical Research Networks, the Adult AIDS Clinical Trials Group (ACTG), the HIV Vaccine Trials Group (HVTN), and the HIV Prevention Trials Group (HPTN). The Penn HIV CTU features an integrated, efficient clinical trials organization with two clinical research sites (CRS), the Penn Therapeutics CRS, located on the Penn School of Medicine (PSOM) campus, that conducts ACTG trials; and the Penn Prevention CRS, separately located on the Penn campus, that conducts HVTN and HPTN supported trials. Penn investigators will continue to contribute to the scientific agendas of these Networks through participation on network committees and through submission of protocols and membership on protocol teams. In addition, the Penn HIV CTU will advance the research agendas of these Networks through the cost efficient implementation of clinical trials to improve the lives of people living with HIV infection and to prevent it among those at risk. The leadership of the Penn HIV CTU will mentor the next generation of clinical investigators by involving junior investigators at our site and elsewhere in activities at that promote their career development at both the Network and site level. Penn investigators will engage the local community affected by HIV when formulating priorities, we will inform the community about opportunities to participate in research, and educate the community about medical advances and opportunities to access them. Penn investigators have contributed to important advances in HIV therapeutics through the evaluation of strategies designed to control HIV replication in the absence of antiretrovirals and purge the latent reservoir, testing of novel agents to inhibit HIV replication, and by improving treatments and prevention of co-morbid conditions associated with HIV infection. Penn investigators have also contributed to advances in HIV prevention through the testing of HIV vaccines, long-acting antiretrovirals and monoclonal antibodies for pre-exposure prophylaxis, and through behavioral interventions designed to modify risk behaviors. It is our goal to make these advances available to all populations living with or at-risk for HIV infection, including men who have sex with men, cisgender women, transgender and gender non-conforming individuals, and persons who inject drugs. Given the resources, vision, and commitment of Penn investigators, the Penn HIV CTU is well positioned to support the initiative for Ending the HIV Epidemic in Philadelphia, a priority city, through achievements in HIV prevention, diagnosis, treatment.

摘要